Industry News

New virtual screening strategy identifies existing drug that inhibits COVID-19 virus

01/05/2021

Excerpt from the Article: A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat Covid-19. Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China, and colleagues present these findings in the open-access journal PLOS Computational…

Read More

Study points the way to boost immunotherapy against breast cancer, other solid tumors

01/04/2021

Excerpt from the Article: Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Center. The boost helps recruit more…

Read More

UCLH doses first patient in the world in Covid-19 antibody trial

01/01/2021

Excerpt from the Press Release: UCLH has opened a new vaccine research centre with two clinical trials testing a long-acting antibody combination treatment to protect against Covid-19. Researchers in the STORM CHASER study led by UCLH virologist Dr Catherine Houlihan have recruited the first participant in the world to the study. They believe the antibody…

Read More

Triple chemotherapy combination improves metastatic colorectal cancer outcomes

12/31/2020

Excerpt from the Press Release: Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination – of irinotecan, cetuximab, and vemurafenib – is a more powerful tumor fighter and keeps people with metastatic…

Read More

Global trial reveals life saving drug for acute myeloid leukemia

12/30/2020

Excerpt from the Article: A landmark paper published today in the New England Journal of Medicine describes the results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement in survival in patients with acute myeloid leukemia (AML).  The Phase 3 clinical trial called QUAZAR, showed that a drug,…

Read More

AstraZeneca: Shot will be effective against COVID-19 variant

12/29/2020

Excerpt from the Article: The head of drugmaker AstraZeneca, which is developing a coronavirus vaccine widely expected to be approved by U.K. authorities this week, said Sunday that researchers believe the shot will be effective against a new variant of the virus driving a rapid surge in infections in Britain. AstraZeneca chief executive Pascal Soriot…

Read More

Telemedicine in the Operating Room: The ‘New Normal’ for MedTech

12/28/2020

Excerpt from the Article: There is incredibly high demand for collaboration during medical procedures – whether it’s a Cardiologist advising a more junior physician on a complex procedure, a renowned surgeon training other colleagues on a technique, a medical device company rolling out a new product, or a medical device rep providing product support during…

Read More

HKU chemists develop a new drug discovery strategy for “undruggable” drug targets

12/28/2020

Excerpt from the Article: A research team led by Dr Xiaoyu LI from the Research Division for Chemistry, Faculty of Science, in collaboration with Professor Yizhou LI from School of Pharmaceutical Sciences, Chongqing University and Professor Yan CAO from School of Pharmacy, Second Military Medical University in Shanghai has developed a new drug discovery method…

Read More

Early data suggest wearables can catch some cases of Covid-19 before symptoms emerge

12/25/2020

Excerpt from the Article: The results of several ambitious studies testing wearables as early predictors of for Covid-19 are in — and they suggest that data from devices including Apple Watches, Fitbits, and Oura smart rings may be useful for flagging some infections in people before they even feel ill. Recently published research from ongoing…

Read More

Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

12/24/2020

Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Incyte (Nasdaq:INCY) today announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi®), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did not meet its primary endpoint. Initial data show that…

Read More